Print this page

PAGES: 838-843 DOI: 10.1590/0074-02760160478 Full paper
Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)

Lucia Regina Brahim1,6,+, Cláudia Maria Valete-Rosalino1,2, Liliane de Fátima Antônio1, Maria Inês Fernandes Pimentel1,4, Marcelo Rosandiski Lyra1, Luiz Eduardo de Carvalho Paes1,3, Ananda Dutra da Costa1, Iracema Forni Vieira1, Cristina Maria Giordano Dias4, Maria Cristina de Oliveira Duque1,5, Mauro Celio de Almeida Marzochi1, Armando de Oliveira Schubach1

1Fundação Oswaldo Cruz-Fiocruz, Instituto Nacional de Infectologia Evandro Chagas, Laboratório de Pesquisa Clínica e Vigilância em Leishmanioses, Rio de Janeiro, RJ, Brasil
2Universidade Federal do Rio de Janeiro, Departamento de Otorrinolaringologia e Oftalmologia, Rio de Janeiro, RJ, Brasil
3Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Pesquisas em Leishmanioses, Rio de Janeiro, RJ, Brasil
4Secretaria de Estado de Saúde do Rio de Janeiro, Vigilância Epidemiológica, Rio de Janeiro, RJ, Brasil
5Secretaria Municipal de Saúde de Timóteo, Timóteo, MG, Brasil
6Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório Interdisciplinar de Vigilância Entomológica em Diptera e Hemiptera, Rio de Janeiro, RJ, Brasil


BACKGROUND American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents with cutaneous (CL) and mucosal (ML) clinical forms. ATL treatment aims at healing the lesions and preventing the development of the late mucosal form. Systemic meglumine antimoniate (MA) therapy with 10-20 mg Sb5+/kg/day is the first choice of treatment. However, alternative therapies using 5 mg Sb5+/kg/day or intralesional (IL) MA are the usual regimens at the National Institute of Infectious Diseases (NIID), Rio de Janeiro, Brazil.

OBJECTIVES To evaluate lethality and the incidence of relapse and development of late ML in CL patients treated at NIID from 2001 until 2013.

METHODS Data were recovered from records of all ATL patients diagnosed during that period.

FINDINGS Out of 777 patients, 753 were treated with MA (96.9%). Of those, 89.1% received alternative therapy of 9.9% IL and 79.2% systemic 5 mg Sb5+/kg/day. Some patients required 1-3 additional courses of treatment, thus making a total of 997 courses; 85.2% of them were subjected to alternative therapies. Lethality was 0.1%, relapse incidence 5.8%, and late ML incidence 0.25%. As a final outcome for the 777 patients, 95.9% were cured, 0.1% died and 4.0% were not able to follow-up.

MAIN CONCLUSIONS Alternative MA schedules resulted in low lethality without increase of relapse or late ML incidence.

key words:

Financial support: CNPq, FAPERJ.
AOS is the recipient of fellowships from CNPq and FAPERJ, Brazil; CMVR is the recipient of fellowship from FAPERJ, Brazil; MCAM is the recipient of fellowship from CNPq, Brazil.
+ Corresponding author: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Received 1 November 2016
Accepted 23 June 2017